companydata.dkAptol Pharma ApS: Financial statements 2018
CVR: 39308967
Aptol Pharma ApS (CVR 39308967) has filed annual accounts for 2018. In 2018, the company reported revenue of DKK 0 and a net result of DKK 128,964. Equity amounted to DKK 50,000. The solvency ratio was 66.3%.
- Revenue
- 0 kr.
- Gross Profit
- 89,482 kr.
- Profit/Loss
- 128,964 kr.
- Equity
- 50,000 kr.
- Total Assets
- 75,402 kr.
Keep an eye on Aptol Pharma ApS
Get notified instantly about new financial statements, ownership changes, management changes and status changes.
Set up monitoringEvents in 2018
As of February 5, 2018, Kira Gerber Astakhova has joined the board of directors of Aptol Pharma ApS.
As of February 5, 2018, Kira Gerber Astakhova is registered as director of Aptol Pharma ApS.
Aptol Pharma ApS was founded on February 5, 2018.
About Aptol Pharma ApS
Aptol Pharma ApS was a Danish company of the type Anpartsselskab based in København SV, founded in 2018. The company was registered under the industry Forskning og eksperimentel udvikling inden for naturvidenskab og teknik. The company was previously named IBIO TECH ApS and Integrated biomedical technologies ApS. The company's owners include Tue Wenzel Kragstrup, Peter Andreas Nicolai Reumert Wagtmann and ADT HOLDING ApS. In 2024, the company reported a gross profit of DKK 2,442 and a net result of DKK -131,289 compared with DKK 307,979 the year before. Equity amounted to DKK -140,336.